Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
Public ClinicalTrials.gov record NCT02471183. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Multicenter, Open-label, Single-group Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Adult Patients With Pulmonary Arterial Hypertension
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral treatment (selexipag) targeting the disease in a similar way. The purpose of the study is i) to investigate the safety and tolerability of oral selexipag in patients who transition from inhaled treprostinil, ii) to investigate the effects of oral selexipag on PAH severity and exercise ability before and after transition, and iii) to gain new information about the patients experience taking oral selexipag compared to inhaled treprostinil. Study participants may stay in the study until the FDA has granted marketing authorization.
Study identification
- NCT ID
- NCT02471183
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 34 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 12, 2015 (Actual)
- Primary completion
- Dec 5, 2016 (Actual)
- Completion
- Dec 5, 2016 (Actual)
- Last update posted
- Jan 23, 2018
2015 – 2016
United States locations
- U.S. sites
- 15
- U.S. states
- 9
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSD Medical Center -La Jolla | La Jolla | California | — | — |
| UCSF Medical Center | San Francisco | California | — | — |
| Harbor UCLA Medical Center | Torrance | California | — | — |
| Emory University | Atlanta | Georgia | — | — |
| Piedmont Healthcare Research Institute | Austell | Georgia | — | — |
| Kentuckiana Pulmonary Associates | Louisville | Kentucky | — | — |
| University of Michigan Health System | Ann Arbor | Michigan | — | — |
| Washington University School of Medicine | St Louis | Missouri | — | — |
| Duke Unversity | Durham | North Carolina | — | — |
| University of Pennsylvania | Philadelphia | Pennsylvania | — | — |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | — | — |
| University of Pittsburgh Medical Center Health System | Pittsburgh | Pennsylvania | — | — |
| UT Southwestern | Dallas | Texas | — | — |
| Houston Methodist Hospital | Houston | Texas | — | — |
| Sentara Cardiovascular Research Instistute | Norfolk | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02471183, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 23, 2018 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02471183 live on ClinicalTrials.gov.